Apical Biotek And Phinest Cannabis Team Up For New Tissue Culture Joint Venture: Steristarts

Green Capital Investments, parent of Phinest Cannabis, and Apical Biotek, announced a new tissue culture laboratory joint venture called Steristarts. The new company's mission is to provide tissue culture technology, genetics, and nursery operations to cannabis cultivators worldwide. Steristarts will also function as the cornerstone of Phinest's California cannabis nursery operation. The new company will be housed inside Phinest Cannabis' 40k ft² nursery facility in Sacramento.

Steristarts succeeds Phinest's previous vendor. "We'd like to thank our previous tissue culture vendor's team for a long and fruitful relationship," stated Fred Barnum, CEO of Phinest Cannabis, "as Phinest explores opportunities outside of California, we're at a point where owning this technology and process presents the best strategic step forward."

Apical Biotek CEO, Justin Givens stated: "Our tech has proven effective in completely removing HpLVd, with 0% re-emergence of HpLVd several years after subjecting germplasm to our proprietary initiation procedures. Our proprietary methods and tech allow us to produce mother stock that's higher yielding and production-ready faster, thus improving the overall efficiency of nursery operations. We know this because Apical Biotek anchored its own nursery operations around mother plants produced by our techniques."

This venture opens the door to hundreds of new genetic licensing opportunities and additional breeder relationships with Phinest. "Thanks to their stellar reputation, Justin and his team have built a library of more than 400 cannabis cultivars and a network of superior breeders," stated Dakota Sullivan, VP of sales for Phinest Cannabis. "We're excited to combine resources, especially as we expand into territories that haven't had access to clean and proven genetics."

Photo: Benzinga edit with photos by geralt and lindsayfox on Pixabay